1021O Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies
Michael Millward, Sophia Frentzas, Hui Gan, Amy Prawira, Ben Tran, Jermaine Coward, Xingsheng Jin, B. Li, M. Wang, Kon Yew Kwek, Yu Xia, Jayesh Desai
Topics & Concepts
MedicinePemetrexedInternal medicineNivolumabMesotheliomaRefractory (planetary science)Response Evaluation Criteria in Solid TumorsOncologyChemotherapyProgressive diseaseIpilimumabAdverse effectGastroenterologySurgeryImmunotherapyCancerPathologyCisplatinAstrobiologyPhysicsCancer Research and TreatmentsOccupational and environmental lung diseasesNeuroblastoma Research and Treatments